Please login to the form below

Not currently logged in
Email:
Password:

EMA’s head of international affairs steps down

Emer Cooke will take up new post at the WHO in November

EMA Emer CookeThe European Medicines Agency's (EMA) Emer Cooke has resigned as head of international affairs, to be replaced ad interim by Agnès Saint-Raymond.

Cooke first joined the EMA in 2002 and has since occupied a number of senior posts including head or international and European cooperation, and head of inspections.

She has served as head of international affairs since 2013, and is leaving the agency to pursue a new role at the World Health Organization (WHO).

From mid-November, Cooke will take up the head of regulation of medicines and other health technologies position in the WHO's essential medicines and health products department, based in Geneva, Switzerland.

Guido Rasi, executive director of the EMA, said: “In her role as head of international affairs, Emer has made a significant contribution to the global recognition of the EU network activities.

“We shall be sorry to lose Emer's insight and expertise, but are confident that she will continue to further develop the close collaboration between EMA and WHO.

“It has been a privilege to work with Emer and we wish her every success in her new role.”

20th September 2016

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics